ArticleAntimicrobial agents and chemotherapy2011
Adaptation and antibiotic tolerance of anaerobic Burkholderia pseudomallei.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 81 citations in OpenAlex.
- Laboratory strategies for the identification of Burkholderia species: From classical phenotyping to advanced genomic and proteomic approaches.Antonie van Leeuwenhoek · 2026Review
- Impact of Host and Bacterial Metabolism on Antibiotic Susceptibility.Biochemistry · 2025Review
- Proteomic comparison of epidemic AustralianMicrobiology spectrum · 2025Article
- A nitric oxide-sensing two-component system regulates a range of infection-related phenotypes inmSphere · 2025Article
- Hijacking anaerobic metabolism to restore antibiotic efficacy inApplied and environmental microbiology · 2025Article
- Targeting Anaerobic Respiration inAdvances in wound care · 2024Article
- Enolase Is Implicated in the Emergence of Gonococcal Tolerance to Ceftriaxone.Antibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial activity of nature-inspired molecules against multidrug-resistant bacteria.Frontiers in microbiology · 2023Article
- Deciphering the human antibody response againstFrontiers in immunology · 2023Article
- Metabolic pathways that permitFrontiers in cellular and infection microbiology · 2023Article
- The Global Regulator MftR Controls Virulence and Siderophore Production in Burkholderia thailandensis.Journal of bacteriology · 2022Article
- Tolerance to Ceftriaxone inAntibiotics (Basel, Switzerland) · 2022Article
- Mechanisms of chlorate toxicity and resistance in Pseudomonas aeruginosa.Molecular microbiology · 2022Article
- Distribution of Burkholderia pseudomallei within a 300-cm deep soil profile: implications for environmental sampling.Scientific reports · 2022Article
- The NarX-NarL two-component system regulates biofilm formation, natural product biosynthesis, and host-associated survival in Burkholderia pseudomallei.Scientific reports · 2022Article
- Designing a novel chimeric multi-epitope vaccine againstFrontiers in medicine · 2022Article
- Layered and integrated medical countermeasures againstFrontiers in microbiology · 2022Article
- Environmental Factors Associated With Soil Prevalence of the Melioidosis PathogenFrontiers in microbiology · 2022Article
- Transcriptomics Analysis Uncovers Transient Ceftazidime Tolerance inACS infectious diseases · 2021Article
- Anaerobic Sulfur Oxidation Underlies Adaptation of a Chemosynthetic Symbiont to Oxic-Anoxic Interfaces.mSystems · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The Gram-negative bacterium Burkholderia pseudomallei is the etiological agent of melioidosis and is remarkably resistant to most classes of antibacterials. Even after months of treatment with antibacterials that are relatively effective in vitro, there is a high rate of treatment failure, indicating that this pathogen alters its patterns of antibacterial susceptibility in response to cues encountered in the host. The pathology of melioidosis indicates that B. pseudomallei encounters host microenvironments that limit aerobic respiration, including the lack of oxygen found in abscesses and in the presence of nitric oxide produced by macrophages. We investigated whether B. pseudomallei could survive in a nonreplicating, oxygen-deprived state and determined if this physiological state was tolerant of conventional antibacterials. B. pseudomallei survived initial anaerobiosis, especially under moderately acidic conditions similar to those found in abscesses. Microarray expression profiling indicated a major shift in the physiological state of hypoxic B. pseudomallei, including induction of a variety of typical anaerobic-environment-responsive genes and genes that appear specific to anaerobic B. pseudomallei. Interestingly, anaerobic B. pseudomallei was unaffected by antibacterials typically used in therapy. However, it was exquisitely sensitive to drugs used against anaerobic pathogens. After several weeks of anaerobic culture, a significant loss of viability was observed. However, a stable subpopulation that maintained complete viability for at least 1 year was established. Thus, during the course of human infection, if a minor subpopulation of bacteria inhabited an oxygen-restricted environment, it might be indifferent to traditional therapy but susceptible to antibiotics frequently used to treat anaerobic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.